PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation

Oncotarget

Volumn 6, Issue 6, 2015, Pages 3680-3693

  Levesque, Christine ^a,b   Couture, Frédéric ^a,b   Kwiatkowska, Anna ^a,b   Desjardins, Roxane ^a,b   Guérin, Brigitte ^b,c   Neugebauer, Witold A ^b   Day, Robert ^a,b  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

Multi Leu peptide; PACE4; Peptide inhibitors; Proprotein convertases; Prostate Cancer

Indexed keywords

ACETYL LEUCYLLEUCYLLEUCYLARGINYLVALYLLYSINE AMIDINOBENZYLAMIDE; ACETYL LEUCYLLEUCYLLEUCYLLEUCYLARGINYLVALYLLYSYLARGININE AMIDE; ACETYL[DEXTRO LEUCINE] LEUCYLLEUCYLLEUCYLLEUCYLARGINYLVALYLLYSYLARGININE AMIDE; ACETYL[DEXTRO LEUCINE]LEUCYLLEUCYLLEUCYLARGINYLVALYLLYSINE AMIDINOBENZYLAMIDE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; PCSK6 PROTEIN, HUMAN; PEPTIDOMIMETIC AGENT; SERINE PROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG STABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDOMIMETICS; PROPROTEIN CONVERTASES; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924264140     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2918     Document Type: Article

References (47)

1. Fugère M, Day R. Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition. Trends Pharmacol Sci. 2005; 26:294-301.
2. Couture F, D'Anjou F, Day R. On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications. Biomolecular Concepts. 2011; 2:421-438.
3. Bassi DE, Fu J, Lopez de Cicco R, Klein-Szanto AJ. Proprotein convertases: "master switches" in the regulation of tumor growth and progression. Mol Carcinog. 2005; 44:151-161.
4. Khatib AM, Siegfried G, Chretien M, Metrakos P, Seidah NG. Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol. 2002; 160:1921-1935.
5. Scamuffa N, Siegfried G, Bontemps Y, Ma L, Basak A, Cherel G, Calvo F, Seidah NG, Khatib AM. Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. J Clin Invest. 2008; 118:352-363.
6. Tzimas GN, Chevet E, Jenna S, Nguyen DT, Khatib AM, Marcus V, Zhang Y, Chretien M, Seidah N, Metrakos P. Abnormal expression and processing of the proprotein convertases PC1 and PC2 in human colorectal liver metastases. BMC Cancer. 2005; 5:149.
7. Khatib AM, Siegfried G, Prat A, Luis J, Chretien M, Metrakos P, Seidah NG. Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions. J Biol Chem. 2001; 276:30686-30693.
8. Sun X, Essalmani R, Day R, Khatib AM, Seidah NG, Prat A. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver. Neoplasia. 2012; 14:1122-1131.
9. Kumar V, Behera R, Lohite K, Karnik S, Kundu GC. p38 kinase is crucial for osteopontin-induced furin expression that supports cervical cancer progression. Cancer Res. 2010; 70:10381-10391.
10. Bassi DE, Mahloogi H, Lopez De Cicco R, Klein-Szanto A. Increased furin activity enhances the malignant phenotype of human head and neck cancer cells. Am J Pathol. 2003; 162:439-447.
11. Bassi DE, Mahloogi H, Al-Saleem L, Lopez De Cicco R, Ridge JA, Klein-Szanto AJ. Elevated furin expression in aggressive human head and neck tumors and tumor cell lines. Mol Carcinog. 2001; 31:224-232.
12. Bassi DE, Lopez De Cicco R, Mahloogi H, Zucker S, Thomas G, Klein-Szanto AJ. Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells. Proc Natl Acad Sci U S A. 2001; 98:10326-10331.
13. Cheng M, Watson PH, Paterson JA, Seidah N, Chretien M, Shiu RP. Pro-protein convertase gene expression in human breast cancer. Int J Cancer. 1997; 71:966-971.
14. Cheng M, Xu N, Iwasiow B, Seidah N, Chretien M, Shiu RP. Elevated expression of proprotein convertases alters breast cancer cell growth in response to estrogen and tamoxifen. J Mol Endocrinol. 2001; 26:95-105.
15. Page RE, Klein-Szanto AJ, Litwin S, Nicolas E, Al-Jumaily R, Alexander P, Godwin AK, Ross EA, Schilder RJ, Bassi DE. Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer. Cell Oncol. 2007; 29:289-299.
16. Longuespée R, Couture F, Levesque C, Kwiatkowska A, Desjardins R, Gagnon S, Vergara D, Maffia M, Fournier I, Salzet M, Day R. Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target. Translational Oncology. 2014; 7:410-419.
17. Couture F, D'Anjou F, Desjardins R, Boudreau F, Day R. Role of proprotein convertases in prostate cancer progression. Neoplasia. 2012; 14:1032-1042.
18. D'Anjou F, Routhier S, Perreault JP, Latil A, Bonnel D, Fournier I, Salzet M, Day R. Molecular Validation of PACE4 as a Target in Prostate Cancer. Translational Oncology. 2011; 4:157-172.
19. Becker GL, Lu Y, Hardes K, Strehlow B, Levesque C, Lindberg I, Sandvig K, Bakowsky U, Day R, Garten W, Steinmetzer T. Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases. J Biol Chem. 2012; 287:21992-22003.
20. Becker GL, Sielaff F, Than ME, Lindberg I, Routhier S, Day R, Lu Y, Garten W, Steinmetzer T. Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. Journal of Medicinal Chemistry. 2010; 53:1067-1075.
21. Levesque C, Fugere M, Kwiatkowska A, Couture F, Desjardins R, Routhier S, Moussette P, Prahl A, Lammek B, Appel JR, Houghten RA, D'Anjou F, Dory YL, et al. The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells. Journal of Medicinal Chemistry. 2012; 55:10501-10511.
22. Kwiatkowska A, Couture F, Levesque C, Ly K, Desjardins R, Beauchemin S, Prahl A, Lammek B, Neugebauer W, Dory YL, Day R. Design, Synthesis, and Structure-Activity Relationship Studies of a Potent PACE4 Inhibitor. Journal of Medicinal Chemistry. 2014; 57:98-109.
23. Couture F, Levesque C, Dumulon-Perreault V, Ait-Mohand S, D'Anjou F, Day R, Guerin B. PACE4-Based Molecular Targeting of Prostate Cancer Using an Engineered (64)Cu-Radiolabeled Peptide Inhibitor. Neoplasia. 2014; 16:634-643.
24. Fournier P, Dumulon-Perreault V, Ait-Mohand S, Langlois R, Benard F, Lecomte R, Guerin B. Comparative study of 64Cu/NOTA-[D-Tyr6,betaAla11,Thi13,Nle14]BBN(6-14) monomer and dimers for prostate cancer PET imaging. EJNMMI Res. 2012; 2:8.
25. Werle M, Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006; 30:351-367.
26. Artenstein AW, Opal SM. Proprotein convertases in health and disease. N Engl J Med. 2011; 365:2507-2518.
27. Bassi DE, Mahloogi H, Klein-Szanto AJ. The proprotein convertases furin and PACE4 play a significant role in tumor progression. Mol Carcinog. 2000; 28:63-69.
28. Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012; 11:367-383.
29. Taylor NA, Van De Ven WJ, Creemers JW. Curbing activation: proprotein convertases in homeostasis and pathology. FASEB J. 2003; 17:1215-1227.
30. Albericio F, Kruger HG. Therapeutic peptides. Future Med Chem. 2012; 4:1527-1531.
31. Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chem Biol Drug Des. 2013; 81:136-147.
32. Bellmann-Sickert K, Beck-Sickinger AG. Peptide drugs to target G protein-coupled receptors. Trends Pharmacol Sci. 2010; 31:434-441.
33. Kaspar AA, Reichert JM. Future directions for peptide therapeutics development. Drug Discov Today. 2013; 18:807-817.
34. Matsui M, Fowler JH, Walling LL. Leucine aminopeptidases: diversity in structure and function. Biol Chem. 2006; 387:1535-1544.
35. Dahms SO, Hardes K, Becker GL, Steinmetzer T, Brandstetter H, Than ME. X-ray Structures of Human Furin in Complex with Competitive Inhibitors. ACS Chem Biol. 2014; 9:1113-1118.
36. Pollaro L, Heinis C. Strategies to prolong the plasma residence time of peptide drugs. MedChemComm. 2010; 1:319-324.
37. Reynolds AR, Kyprianou N. Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. Br J Pharmacol. 2006; 147:S144-152.
38. Mukherji D, Temraz S, Wehbe D, Shamseddine A. Angiogenesis and anti-angiogenic therapy in prostate cancer. Crit Rev Oncol Hematol. 2013; 87:122-131.
39. Wozney JL, Antonarakis ES. Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. Cancer Metastasis Rev. 2014; 33:581-594.
40. Toren PJ, Gleave ME. Novel non-AR therapeutic targets in castrate resistant prostate cancer. Translational Andrology and Urology. 2013; 2:265-277.
41. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
42. Sluka P, Davis ID. Cell mates: paracrine and stromal targets for prostate cancer therapy. Nat Rev Urol. 2013; 10:441-451.
43. Malfait AM, Seymour AB, Gao F, Tortorella MD, Le Graverand-Gastineau MP, Wood LS, Doherty M, Doherty S, Zhang W, Arden NK, Vaughn FL, Leaverton PE, Spector TD, et al. A role for PACE4 in osteoarthritis pain: evidence from human genetic association and null mutant phenotype. Ann Rheum Dis. 2012; 71:1042-1048.
44. Guerin B, Ait-Mohand S, Tremblay MC, Dumulon-Perreault V, Fournier P, Benard F. Total solid-phase synthesis of NOTA-functionalized peptides for PET imaging. Org Lett. 2010; 12:280-283.
45. Fugère M, Limperis PC, Beaulieu-Audy V, Gagnon F, Lavigne P, Klarskov K, Leduc R, Day R. Inhibitory potency and specificity of subtilase-like pro-protein convertase (SPC) prodomains. J Biol Chem. 2002; 277:7648-7656.
46. Selivanov V, Picard Y, Cadorette J, Rodrigue S, Lecomte R. Detector response models for statistical iterative image reconstruction in high resolution PET. Nuclear Science Symposium, 1998 Conference Record IEEE. 1998; 1372:1377-1381.
47. Pham NA, Morrison A, Schwock J, Aviel-Ronen S, Iakovlev V, Tsao MS, Ho J, Hedley DW. Quantitative image analysis of immunohistochemical stains using a CMYK color model. Diagn Pathol. 2007; 2:8.